PARIS--(BUSINESS WIRE)--Regulatory News:
AREVA Med (Paris:AREVA) has launched operations at its second high-purity lead-212 (212Pb) production facility located in Plano, Texas. Known as the DDPU (Domestic Distribution and Purification Unit), this facility was officially inaugurated this week.
Lead-212 is used in Targeted Alpha Therapy (TAT) in an increasing number of innovative studies to target cancer cells, while limiting the impact on nearby healthy cells.
In a centralized modular plant, the DDPU will hold all AREVA Med’s U.S. activities and those of its subsidiary Macrocyclics, the global leader in the design and manufacturing of chelating agents* for nuclear medicine. With brand new equipment, this state-of-the-art facility, which will employ 10 people, is an opportunity for AREVA Med to expand the range and increase the quality of products and services for its American partners and customers. Thanks to this increased production capacity, AREVA Med will accelerate the development of innovative Targeted Alpha Therapies using lead-212 to combat cancer.
Patrick Bourdet, AREVA Med’s CEO said: “Our new modular and unique US plant will allow us to quickly expand our cancer therapy pipeline and increase collaboration within the entire continent.”
*A chelating agent is a “molecular cage” used to attach isotopes to biological carriers such as monoclonal antibodies targeting cancer cells.
MORE ABOUT AREVA
AREVA supplies high added-value products and services to support the operation of the global nuclear fleet.
The company is present throughout the entire nuclear cycle, from uranium mining to used fuel recycling, including nuclear reactor design and operating services.
AREVA is recognized by utilities around the world for its expertise, its skills in cutting-edge technologies and its dedication to the highest level of safety.
AREVA’s 40,000 employees are helping build tomorrow’s energy model: supplying ever safer, cleaner and more economical energy to the greatest number of people.